Tourmaline Bio’s Heart Drug Pacibekitug Shows Promise Against Cardiovascular Inflammation, Targets Competition with Novo, CSL

Tourmaline Bio's drug pacibekitug has shown positive topline results in reducing inflammation markers in a heart disease study, according to recent Phase 2 data2.

The company is preparing to initiate discussions with the FDA for a potential Phase 3 trial as it seeks to compete with cardiovascular assets from industry leaders such as Novo Nordisk and CSL2.

Pacibekitug targets IL-6-driven cardiovascular inflammation, a pathway gaining increasing recognition for its role in atherosclerotic cardiovascular disease3.

Tourmaline's clinical focus includes developing pacibekitug for atherosclerotic cardiovascular disease (ASCVD), abdominal aortic aneurysm, and thyroid eye disease, with further details expected following the full readout of the Phase 2 TRANQUILITY trial45.

Tourmaline Bio highlighted strong financials, with a reported cash runway expected into the second half of 2027, supporting continued development of pacibekitug and other pipeline programs5.

Sources:

2. https://endpts.com/tourmaline-bios-heart-drug-cuts-inflammation-as-it-seeks-to-compete-with-novo-csls-assets/

3. https://ir.tourmalinebio.com/news-releases/news-release-details/tourmaline-bio-reports-first-quarter-2025-financial-results-and

4. https://ir.tourmalinebio.com/news-releases/news-release-details/tourmaline-bio-highlights-cardiovascular-inflammation-focus-and

5. https://www.biospace.com/press-releases/tourmaline-bio-reports-first-quarter-2025-financial-results-and-recent-business-highlights